What's Happening?
C2N Diagnostics has received a laboratory permit from the New York State Department of Health, allowing it to offer its PrecivityAD2 and PrecivityAD blood tests for Alzheimer's disease diagnosis in New York.
This expansion means the tests are now available in all 50 states, aiding healthcare professionals in detecting amyloid plaques in the brain, a hallmark of Alzheimer's disease. The permit reflects C2N's commitment to high-quality standards and accuracy, providing a convenient and affordable diagnostic tool for the growing older population in New York. The tests are intended for patients aged 50 and older with signs of mild cognitive impairment or dementia.
Why It's Important?
The availability of C2N's blood tests in New York is a significant development in Alzheimer's disease diagnosis, offering a non-invasive and accessible option for early detection. Early diagnosis is crucial for managing Alzheimer's, allowing patients to access disease-modifying therapies and make lifestyle adjustments. The tests support informed medical management and treatment decisions, potentially improving patient outcomes. As the population ages, the demand for effective diagnostic tools will increase, making C2N's expansion a timely and impactful advancement in brain health diagnostics.
